FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
ELOX Financial Statements
Year
2022
2021
2020
2019
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
34.42M
66.02M
29.44M
50.55M
Research and Development
23.73M
45.57M
14.59M
26.35M
Selling, General & Administrative Expenses
10.69M
20.45M
14.85M
24.21M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
10.69M
20.45M
14.85M
24.21M
Other Expenses
0
0
0
0
Operating Income
-34.42M
-66.02M
-33.45M
-50.55M
Total Other Income/Expenses Net
-1.65M
-709k
-1.12M
-319k
Income Before Tax
-36.06M
-66.73M
-34.58M
-50.87M
Income Tax
0
1.26M
1.41M
1.62M
Net Income
-36.06M
-66.73M
-34.58M
-50.87M
Basic EPS
-16.65
-38.15
-34.47
-53.46
EPS Diluted
-16.65
-38.15
-34.47
-53.46
Basic Average Shares
2.17M
1.75M
1M
951.58k
Diluted Average Shares
2.17M
1.75M
1M
951.58k
EBITDA
-33.37M
-66.02M
-33.45M
-50.55M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-238.32M
-171.6M
-137.02M
-86.14M
Net Income
-36.06M
-66.73M
-34.58M
-50.87M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-274.39M
-238.32M
-171.6M
-137.02M
Other Distributions
-36.06M
-66.73M
-34.58M
-50.87M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
994k
1.66M
554k
1.13M
Annual Depreciation
695k
960k
571k
559k
Capital Expenditure
-66k
-89k
0
-40k
Net PPE
365k
788k
-17k
606k
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
